Chin Med J (Engl). 2024 Dec 20;137(24):2907-2952. doi: 10.1097/CM9.0000000000003431. Epub 2024 Dec 9.
In China, hypertension is the most common chronic non-communicable disease and the most significant risk factor for cardiovascular mortality among urban and rural residents. To standardize the clinical diagnosis and treatment of hypertension and to improve the prevention and control level of hypertension in China, Chinese Society of Cardiology, Chinese Medical Association; Hypertension Committee of Cross-Straits Medicine Exchange Association; Cardiovascular Disease Prevention and Rehabilitation Committee, Chinese Association of Rehabilitation Medicine, jointly collaborated to formulate the Clinical Practice Guideline for Hypertension Management in China. The Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to rate the quality of evidence and strength of recommendations, and the reporting items for practice guidelines in healthcare (RIGHT) were followed to establish the guideline. Detailed evidence-based recommendations for the diagnosis, evaluation, and treatment of 44 clinical questions in the field of hypertension, including essential and secondary hypertension, have been provided to guide clinical practice.
International Practice Guidelines Registry Platform, http://www.guidelines-registry.cn/ , No. IPGRP-2021CN346.
在中国，高血压是最常见的慢性非传染性疾病，也是城乡居民心血管疾病死亡的最重要危险因素。为规范中国高血压的临床诊断与治疗，提高高血压的防控水平，中华医学会心血管病学分会、海峡两岸医药卫生交流协会高血压专业委员会、中国康复医学会心血管病预防与康复专业委员会联合协作制定了《中国高血压防治指南》。采用推荐分级的评估、制定与评价（GRADE）方法对证据质量和推荐强度进行评级，并遵循医疗保健实践指南报告条目（RIGHT）来制定本指南。针对高血压领域包括原发性和继发性高血压在内的44个临床问题的诊断、评估和治疗，提供了详细的循证推荐，以指导临床实践。
国际实践指南注册平台，http://www.guidelines-registry.cn/ ，编号IPGRP-2021CN346。
Zotero 插件